The first week of February 2026 will be remembered as the day the pharmaceutical sector’s most famous partnership officially dissolved. For years, Eli Lilly and Company (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) traded in lockstep, their stock charts nearly identical as they raced to supply the world with weight-loss medicines. That era is over.
The market delivered a swift verdict following both companies' financial updates. Eli Lilly shares rose more than 7%, propelling the Indianapolis-based giant back above the $1 trillion market capitalization threshold. Conversely, Novo Nordisk stock tumbled nearly 6%, erasing billions in shareholder value.
